Skip to main content

SQI Diagnostics Announces Stock Option Grant

By November 25, 2020No Comments

Toronto, OntarioMarch 9, 2018SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF),

a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective March 5, 2018, they have granted 4,130,770 stock options as part of a Company-wide long-term incentive plan. The goal of the grant is to align the interest of all employees with those of shareholders. 2,381,944 options have been granted to four officers, one of whom is also a director. Independent directors did not receive options in this grant.

The options were granted at an exercise price of $0.20. Pursuant to the previously approved stock option plan, the options have a term of 5 years and vest over a 36 month period. Following the grant of these options there will be 8,644,000 options outstanding. There are currently 134,936,000 common shares outstanding.

Investor relations contact:

Chief Executive Officer
Andrew Morris
416.674.9500 ext. 229

Vice President of Finance
Patricia Lie
416.674.9500 ext. 277

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit

Forward-looking Statements

This press release contains certain words and statements, which may constitute “forward-looking statements” within the meaning of applicable securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties detailed in the Company’s ongoing filings with the securities regulatory authorities, available to the public at Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.